Palo Alto Investors LP Provention Bio, Inc. Transaction History

Palo Alto Investors LP

  • $727 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$3.43 - $5.62 $1.34 Million - $2.2 Million
390,800 New
390,800 $1.76 Million

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0
View Full List

About Provention Bio, Inc.

PRVB Quotes by TradingView
  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Palo Alto Investors LP Portfolio

Follow Palo Alto Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email